Form 4 for DXR DAXOR CORP
Accepted 2023-11-02 00:00:00 ET · period of report 2023-10-31 · accession 0001493152-23-039200 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-02 | 2023-10-31 | DXR | Michel Robert J | CFO | A - Grant | $0.00 | +2,000 | 9,750 | +26% | $0 |
| D | 2023-11-02 | 2023-10-31 | DXR | Michel Robert J | CFO | A - Grant | $0.00 | +5,000 | 5,000 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Daxor Common Stock | 2023-10-31 | A | A | 2,000 | $0.00 | 9,750 | D | — | — | (F1) Shares granted vest in three (3) equal installments. 666 vest on October 31, 2023; 666 will vest on October 31, 2024; and 668 will vest on October 31, 2025 |
| 2 | Derivative | Stock Options (right to buy) | 2023-10-31 | A | A | 5,000 | $0.00 | 5,000 | D | $7.99 · — to 2028-10-31 | 5,000 COMMON STOCK | (F2) Stock options granted on October 31, 2023 are contingent on certain regulatory approvals. (F3) The stock options will vest in three installments. 1,666 vest on October 31, 2023; 1,666 will vest October 31, 2024; and 1,668 will vest on October 31, 2026. |